Improving the prediction of the brain disposition for orally administered drugs using BDDCS

Advanced Drug Delivery Reviews

Volumn 64, Issue 1, 2012, Pages 95-109

  Broccatelli, Fabio ^a,b   Larregieu, Caroline A ^a   Cruciani, Gabriele ^b   Oprea, Tudor I ^c,d   Benet, Leslie Z ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF PERUGIA   (Italy)

^c UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^d TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

Author keywords

Brain disposition; Data mining; Drug discovery; Rules of thumb

Indexed keywords

BIOLOGICAL FACTORS; BIOPHARMACEUTICS; BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEMS; CLASS 1; CLASSIFICATION SYSTEM; CLASSIFICATION TREES; DATA SETS; DRUG DISCOVERY; HUMAN BODIES; IN-SILICO; IN-SILICO MODELS; IN-VITRO; IN-VIVO; P-GLYCOPROTEIN; PREDICTION ACCURACY; RECEPTOR ANTAGONISTS; RULES OF THUMB; SEDATIVE EFFECT; STRUCTURAL INFORMATION;

CLASSIFICATION (OF INFORMATION); DATA MINING; FORECASTING; TREES (MATHEMATICS);

BRAIN MODELS;

GLYCOPROTEIN P;

BIOPHARMACEUTICS DRUG DISPOSITION CLASSIFICATION SYSTEM; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CLASSIFICATION ALGORITHM; COMPUTER MODEL; DRUG CLASSIFICATION; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG TRANSPORT; PRIORITY JOURNAL; REVIEW;

ADMINISTRATION, ORAL; ANIMALS; BIOPHARMACEUTICS; BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEM AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; MODELS, NEUROLOGICAL; P-GLYCOPROTEINS; PERMEABILITY; PHARMACOKINETICS;

EID: 84858446116     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2011.12.008     Document Type: Review

References (157)

1. Hansch C., Steward A.R., Iwasa J. The correlation of localization rates of benzeneboronic acids in brain and tumor tissue with substituent constants. Mol. Pharmacol. 1965, 1:87-92.
2. Hansch C., Bjorkroth J.P., Leo A. Hydrophobicity and central nervous system agents: on the principle of minimal hydrophobicity in drug design. J. Pharm. Sci. 1987, 76:663-687.
3. Levin V.A. Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J. Med. Chem. 1980, 23:682-684.
4. Ghose A.K., Herbertz T., Hudkins R.L., Dorsey B.D., Mallamo J.P. Knowledge-based, central nervous system (CNS) lead selection and lead optimization for CNS drug discovery. ACS Chem. Neurosci. 2012, 3:50-68.
5. Norinder U., Haeberlein M. Computational approaches to the prediction of the blood-brain distribution. Adv. Drug Deliv. Rev. 2002, 54:291-313.
6. Clark D.E. In silico prediction of blood-brain barrier permeation. Drug Discov. Today 2003, 8:927-933.
7. Ecker G.F., Noe C.R. In silico prediction models for blood-brain barrier permeation. Curr. Med. Chem. 2004, 11:1617-1628.
8. Cordon-Cardo C., O'Brien J.P., Casals D., Rittman-Grauer L., Biedler J.L., Melamed M.R., Bertino J.R. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. 1989, 86:695-698.
9. Cornwell M.M., Tsuruo T., Gottesman M.M., Pastan I. ATP-binding properties of P glycoprotein from multidrug-resistant KB cells. FASEB J. 1987, 1:51-54.
10. Schinkel A.H., Wagenaar E., Mol C.A., van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest. 1996, 97:2517-2524.
11. Mahar Doan K.M., Humphreys J.E., Webster L.O., Wring S.A., Shampine L.J., Serabjit-Singh C.J., Adkison K.K., Polli J.W. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J. Pharmacol. Exp. Ther. 2002, 303:1029-1037.
12. Wager T.T., Ramalakshmi Y.C., Hou X., Troutman M.D., Verhoest P.R., Villalobos A., Will Y. Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes. ACS Chem. Neurosci. 2010, 1:420-434.
13. Wu C.Y., Benet L.Z. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm. Res. 2005, 22:11-23.
14. Custodio J.M., Wu C.Y., Benet L.Z. Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. Adv. Drug Deliv. Rev. 2008, 60:717-733.
15. Shugarts S., Benet L.Z. The role of transporters in the pharmacokinetics of orally administered drugs. Pharm. Res. 2009, 26:2039-2054.
16. Broccatelli F., Cruciani G., Benet L.Z., Oprea T.I. BDDCS class prediction for new molecular entities. Mol. Pharmaceutics 2012, 9:570-580.
17. Cruciani G., Crivori P., Carrupt P.-A., Testa B. Molecular fields in quantitative structure-permeation relationships: the VolSurf approach. J. Mol. Struct. (THEOCHEM) 2000, 503:7-30.
18. Pajouhesh H., Lenz G.R. Medicinal chemical properties of successful central nervous system drugs. NeuroRx 2005, 2:541-553.
19. Polli J.W., Wring S.A., Humphreys J.E., Huang L., Morgan J.B., Webster L.O., Serabjit-Singh C.S. Rational use of in vitro P-glycoprotein assays in drug discovery. J. Pharmacol. Exp. Ther. 2001, 299:620-628.
20. Troutman M.D., Thakker D.R. Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm. Res. 2003, 20:1210-1224.
21. Chen C., Hanson E., Watson J.W., Lee J.S. P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists. Drug Metab. Dispos. 2003, 31:312-318.
22. Chen C., Mireles R.J., Campbell S.D., Lin J., Mills J.B., Xu J.J., Smolarek T.A. Differential interaction of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab. Dispos. 2005, 33:537-546.
23. Wang Q., Rager J.D., Weinstein K., Kardos P.S., Dobson G.L., Li J., Hidalgo I.J. Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier. Int. J. Pharm. 2005, 288:349-359.
24. Kim W.Y., Benet L.Z. P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro. Pharm. Res. 2004, 21:1284-1293.
25. Eriksson U.G., Dorani H., Karlsson J., Fritsch H., Hoffmann K.J., Olsson L., Sarich T.C., Wall U., Schutzer K.M. Influence of erythromycin on the pharmacokinetics of ximelagatran may involve inhibition of P-glycoprotein-mediated excretion. Drug Metab. Dispos. 2006, 34:775-782.
26. Huang L., Wang Y., Grimm S. ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein. Drug Metab. Dispos. 2006, 34:738-742.
27. Baltes S., Gastens A.M., Fedrowitz M., Potschka H., Kaever V., Loscher W. Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology 2007, 52:333-346.
28. Carrara S., Reali V., Misiano P., Dondio G., Bigogno C. Evaluation of in vitro brain penetration: optimized PAMPA and MDCKII-MDR1 assay comparison. Int. J. Pharm. 2007, 345:125-133.
29. Obradovic T., Dobson G.G., Shingaki T., Kungu T., Hidalgo I.J. Assessment of the first and second generation antihistamines brain penetration and role of P-glycoprotein. Pharm. Res. 2007, 24:318-327.
30. Summerfield S.G., Read K., Begley D.J., Obradovic T., Hidalgo I.J., Coggon S., Lewis A.V., Porter R.A., Jeffrey P. Central nervous system drug disposition: the relationship between in situ brain permeability and brain free fraction. J. Pharmacol. Exp. Ther. 2007, 322:205-213.
31. de Souza J., Benet L.Z., Huang Y., Storpirtis S. Comparison of bidirectional lamivudine and zidovudine transport using MDCK, MDCK-MDR1, and Caco-2 cell monolayers. J. Pharm. Sci. 2009, 98:4413-4419.
32. Feng B., Mills J.B., Davidson R.E., Mireles R.J., Janiszewski J.S., Troutman M.D., de Morais S.M. In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system. Drug Metab. Dispos. 2008, 36:268-275.
33. Park M.S., Okochi H., Benet L.Z. Is ciprofloxacin a substrate of P-glycoprotein?. Arch. Drug Inf. 2011, 4:1-9.
34. Benet L.Z., Broccatelli F., Oprea T.I. BDDCS applied to over 900 drugs. AAPS J. 2011, 13:519-547.
35. Kodaira H., Kusuhara H., Ushiki J., Fuse E., Sugiyama Y. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone. J. Pharmacol. Exp. Ther. 2010, 333:788-796.
36. Friden M., Winiwarter S., Jerndal G., Bengtsson O., Wan H., Bredberg U., Hammarlund-Udenaes M., Antonsson M. Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids. J. Med. Chem. 2009, 52:6233-6243.
37. Sasongko L., Link J.M., Muzi M., Mankoff D.A., Yang X., Collier A.C., Shoner S.C., Unadkat J.D. Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clin. Pharmacol. Ther. 2005, 77:503-514.
38. McAuley B.J., Schroeder J.S. The use of diltiazem hydrochloride in cardiovascular disorders. Pharmacotherapy 1982, 2:121-133.
39. Naito K., Nagao T., Otsuka M., Harigaya S., Nakajima H. Penetration into and elimination from the cerebrospinal fluid of diltiazem, a calcium antagonist, in anesthetized rabbits. Arzneimittelforschung 1986, 36:25-28.
40. Zaman R., Jack D.B., Kendall M.J. The penetration of acebutolol and its major metabolite, diacetolol, into human cerebrospinal fluid and saliva. Br. J. Clin. Pharmacol. 1981, 12:427-429.
41. Brenner M., Haass A., Jacobi P., Schimrigk K. Amantadine sulphate in treating Parkinson's disease: clinical effects, psychometric tests and serum concentrations. J. Neurol. 1989, 236:153-156.
42. Lacy C.F., Armstrong L.L., Goldman M.P., Lance L.L. Lexi-Comp's Drug Information Handbook 2011-2012: A Comprehensive Resource for All Clinicians and Healthcare Professionals 2011, Lexi-Comp, Inc., Hudson, Ohio. 20th ed.
43. Edwards J.E., Brouwer K.R., McNamara P.J. GF120918, a P-glycoprotein modulator, increases the concentration of unbound amprenavir in the central nervous system in rats. Antimicrob. Agents Chemother. 2002, 46:2284-2286.
44. Cheng Z., Zhang J., Liu H., Li Y., Zhao Y., Yang E. Central nervous system penetration for small molecule therapeutic agents does not increase in multiple sclerosis- and Alzheimer's disease-related animal models despite reported blood-brain barrier disruption. Drug Metab. Dispos. 2010, 38:1355-1361.
45. Kurz H. The permeation of drugs across the so-called blood-brain-barrier at low temperature. Experientia 1964, 20:96-97.
46. Simons F.E., Fraser T.G., Reggin J.D., Simons K.J. Comparison of the central nervous system effects produced by six H1-receptor antagonists. Clin. Exp. Allergy 1996, 26:1092-1097.
47. Cruickshank J.M., Neil-Dwyer G., Cameron M.M., McAinsh J. Beta blockers and the central nervous system (CNS). Abstract. 6th Sci. Meet. Int. Soc. Hypertension, Goteborg, Sweden 1979.
48. Preskorn S.H., Othmer S.C. Evaluation of bupropion hydrochloride: the first of a new class of atypical antidepressants. Pharmacotherapy 1984, 4:20-34.
49. Nehlig A., Daval J.L., Debry G. Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects. Brain Res. Rev. 1992, 17:139-170.
50. Kossmann T., Hans V., Stocker R., Imhof H.G., Joos B., Trentz O., Morganti-Kossmann M.C. Penetration of cefuroxime into the cerebrospinal fluid of patients with traumatic brain injury. J. Antimicrob. Chemother. 1996, 37:161-167.
51. Product Information: Zyrtec®, Cetirizine Hydrochloride 1999, Pfizer Inc, New York, NY.
52. Adjene J.O., Adenowo T.K. Histological studies of the effects of chronic administration of chloroquine on the inferior colliculus of the adult Wistar rat. J. Med. Biomed. Res. 2005, 4:83-87.
53. Product Information: Diuril®, Chlorothiazide Sodium Intravenous 1999, Merck & Co., Inc., West Point, PA.
54. Gilman A.G., Goodman L.S., Rall T.W., Murad F. Goodman and Gilman's The Pharmacological Basis of Therapeutics 1985, Macmillan Publishing Co., New York, NY. 7th ed.
55. Lin J.H. Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Relationship between intrinsic potency and effective plasma concentrations. Clin. Pharmacokinet. 1991, 20:218-236.
56. Anon Clarithromycin. Anon: Phase III Profiles, I 1990, 1-4. Biomega Corporation, Skokie, IL.
57. Turner R.B., Sperber S.J., Sorrentino J.V., O'Connor R.R., Rogers J., Batouli A.R., Gwaltney J.M. Effectiveness of clemastine fumarate for treatment of rhinorrhea and sneezing associated with the common cold. Clin. Infect. Dis. 1997, 25:824-830.
58. Desrayaud S., Guntz P., Scherrmann J.M., Lemaire M. Effect of the P-glycoprotein inhibitor, SDZ PSC 833, on the blood and brain pharmacokinetics of colchicine. Life Sci. 1997, 61:153-163.
59. Lensmeyer G.L., Wiebe D.A., Carlson I.H., Subramanian R. Concentrations of cyclosporin A and its metabolites in human tissues postmortem. J. Anal. Toxicol. 1991, 15:110-115.
60. Balis F.M., Lester C.M., Chrousos G.P., Heideman R.L., Poplack D.G. Differences in cerebrospinal fluid penetration of corticosteroids: possible relationship to the prevention of meningeal leukemia. J. Clin. Oncol. 1987, 5:202-207.
61. Schwartz M.A., Koechlin B.A., Postma E., Palmer S., Krol G. Metabolism of diazepam in rat, dog, and man. J. Pharmacol. Exp. Ther. 1965, 149:423-435.
62. Mayer U., Wagenaar E., Dorobek B., Beijnen J.H., Borst P., Schinkel A.H. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J. Clin. Invest. 1997, 100:2430-2436.
63. Au-Yeung S.C., Rurak D.W., Gruber N., Riggs K.W. A pharmacokinetic study of diphenhydramine transport across the blood-brain barrier in adult sheep: potential involvement of a carrier-mediated mechanism. Drug Metab. Dispos. 2006, 34:955-960.
64. Stein M.B., Black B., Brown T.M., Uhde T.W. Lack of efficacy of the adenosine reuptake inhibitor dipyridamole in the treatment of anxiety disorders. Biol. Psychiatry 1993, 33:647-650.
65. Product Information: Motilium®, Domperidone Maleate 1999, Janssen-Ortho, Toronto, Ontario, Canada.
66. Scheld W.M. Quinolone therapy for infections of the central nervous system. Rev. Infect. Dis. 1989, 11(Suppl. 5):S1194-S1202.
67. Perrin V.L. Clinical pharmacokinetics of ergotamine in migraine and cluster headache. Clin. Pharmacokinet. 1985, 10:334-352.
68. Bergan T., Hellum K.B., Schreiner A., Digranes A., Josefsson K. Passage of erythromycin into human suction skin blisters. Curr. Ther. Res. 1982, 32:597-603.
69. Piredda S., Monaco F. Ethosuximide in tears, saliva, and cerebrospinal fluid. Ther. Drug Monit. 1981, 3:321-323.
70. Hande K.R., Wedlund P.J., Noone R.M., Wilkinson G.R., Greco F.A., Wolff S.N. Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients. Cancer Res. 1984, 44:379-382.
71. Zhao R., Kalvass J.C., Yanni S.B., Bridges A.S., Pollack G.M. Fexofenadine brain exposure and the influence of blood-brain barrier P-glycoprotein after fexofenadine and terfenadine administration. Drug Metab. Dispos. 2009, 37:529-535.
72. Curry S.H., Whelpton R., de Schepper P.J., Vranckx S., Schiff A.A. Kinetics of fluphenazine after fluphenazine dihydrochloride, enanthate and decanoate administration to man. Br. J. Clin. Pharmacol. 1979, 7:325-331.
73. Chen C. Physicochemical, pharmacological and pharmacokinetic properties of the zwitterionic antihistamines cetirizine and levocetirizine. Curr. Med. Chem. 2008, 15:2173-2191.
74. Letendre S.L., Capparelli E.V., Ellis R.J., McCutchan J.A. Indinavir population pharmacokinetics in plasma and cerebrospinal fluid. The HIV Neurobehavioral Research Center Group. Antimicrob. Agents Chemother. 2000, 44:2173-2175.
75. Bannwarth B., Netter P., Lapicque F., Pere P., Thomas P., Gaucher A. Plasma and cerebrospinal fluid concentrations of indomethacin in humans. Relationship to analgesic activity. Eur. J. Clin. Pharmacol. 1990, 38:343-346.
76. Tucker R.M., Denning D.W., Dupont B., Stevens D.A. Itraconazole therapy for chronic coccidioidal meningitis. Ann. Intern. Med. 1990, 112:108-112.
77. Product Information: Nizoral® Tablets, Ketoconazole 1998, Janssen Pharmaceutica, Inc., Titusville, NJ.
78. Product Information: Labetalol HCl Oral Tablets 2004, Eon Labs, Inc., Laurelton, NY.
79. Elkiweri I.A., Zhang Y.L., Christians U., Ng K.Y., Tissot van Patot M.C., Henthorn T.K. Competitive substrates for P-glycoprotein and organic anion protein transporters differentially reduce blood organ transport of fentanyl and loperamide: pharmacokinetics and pharmacodynamics in Sprague-Dawley rats. Anesth. Analg. 2009, 108:149-159.
80. Product Information: Claritin-D® 12 HOUR, Loratadine/Pseudoephedrine 1999, Schering Corporation, Kenilworth, NJ.
81. Product Information: Methotrexate LPF®, Methotrexate 2003, Xanodyne Pharmacal, Inc., Florence, KY.
82. Chen T.C., Mackic J.B., McComb J.G., Giannotta S.L., Weiss M.H., Zlokovic B.V. Cellular uptake and transport of methylprednisolone at the blood-brain barrier. Neurosurgery 1996, 38:348-354.
83. Liu X., Van Natta K., Yeo H., Vilenski O., Weller P.E., Worboys P.D., Monshouwer M. Unbound drug concentration in brain homogenate and cerebral spinal fluid at steady state as a surrogate for unbound concentration in brain interstitial fluid. Drug Metab. Dispos. 2009, 37:787-793.
84. Product Information: Lopressor®, Metoprolol 1999, Novartis Pharmaceutical, East Hanover, NJ.
85. Ohara S., Hayashi R., Momoi H., Miki J., Yanagisawa N. Mexiletine in the treatment of spasmodic torticollis. Mov. Disord. 1998, 13:934-940.
86. Aweeka F., Jayewardene A., Staprans S., Bellibas S.E., Kearney B., Lizak P., Novakovic-Agopian T., Price R.W. Failure to detect nelfinavir in the cerebrospinal fluid of HIV-1-infected patients with and without AIDS dementia complex. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 1999, 20:39-43.
87. Takakura S., Sogabe K., Satoh H., Mori J., Fujiwara T., Totsuka Z., Tokuma Y., Kohsaka M. Nilvadipine as a neuroprotective calcium entry blocker in a rat model of global cerebral ischemia. A comparative study with nicardipine hydrochloride. Neurosci. Lett. 1992, 141:199-202.
88. Uchida S., Yamada S., Nagai K., Deguchi Y., Kimura R. Brain pharmacokinetics and in vivo receptor binding of 1,4-dihydropyridine calcium channel antagonists. Life Sci. 1997, 61:2083-2090.
89. Manjunath K., Venkateswarlu V. Pharmacokinetics, tissue distribution and bioavailability of nitrendipine solid lipid nanoparticles after intravenous and intraduodenal administration. J. Drug Target. 2006, 14:632-645.
90. McDevitt D.G. Comparison of pharmacokinetic properties of beta-adrenoceptor blocking drugs. Eur. Heart J. 1987, 8(Suppl. M):9-14.
91. Battino D., Estienne M., Avanzini G. Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part II. Phenytoin, carbamazepine, sulthiame, lamotrigine, vigabatrin, oxcarbazepine and felbamate. Clin. Pharmacokinet. 1995, 29:341-369.
92. Maher V.M., Thompson G.R. HMG CoA reductase inhibitors as lipid-lowering agents: five years experience with lovastatin and an appraisal of simvastatin and pravastatin. Q. J. Med. 1990, 74:165-175.
93. Zhou L., Schmidt K., Nelson F.R., Zelesky V., Troutman M.D., Feng B. The effect of breast cancer resistance protein and P-glycoprotein on the brain penetration of flavopiridol, imatinib mesylate (Gleevec), prazosin, and 2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid (PF-407288) in mice. Drug Metab. Dispos. 2009, 37:946-955.
94. Taylor E.A., Jefferson D., Carroll J.D., Turner P. Cerebrospinal fluid concentrations of propranolol, pindolol and atenolol in man: evidence for central actions of beta-adrenoceptor antagonists. Br. J. Clin. Pharmacol. 1981, 12:549-559.
95. Ochs H.R., Greenblatt D.J., Lloyd B.L., Woo E., Sonntag M., Smith T.W. Entry of quinidine into cerebrospinal fluid. Am. Heart J. 1980, 100:341-346.
96. Kagevi I., Wahlby L. CSF concentrations of ranitidine. Lancet 1985, 1:164-165.
97. Product Information: Reserpine Oral Tablets 2004, Eon Labs, Inc., Laurelton, NY.
98. Kravcik S., Gallicano K., Roth V., Cassol S., Hawley-Foss N., Badley A., Cameron D.W. Cerebrospinal fluid HIV RNA and drug levels with combination ritonavir and saquinavir. J. Acquir. Immune Defic. Syndr. 1999, 21:371-375.
99. Wang C., Quan L.H., Guo Y., Liu C.Y., Liao Y.H. Uptake and biodistribution of rizatriptan to blood and brain following different routes of administration in rats. Int. J. Pharm. 2007, 337:155-160.
100. Ose A., Kusuhara H., Endo C., Tohyama K., Miyajima M., Kitamura S., Sugiyama Y. Functional characterization of mouse organic anion transporting peptide 1a4 in the uptake and efflux of drugs across the blood-brain barrier. Drug Metab. Dispos. 2010, 38:168-176.
101. Chen C., Lin J., Smolarek T., Tremaine L. P-glycoprotein has differential effects on the disposition of statin acid and lactone forms in mdr1a/b knockout and wild-type mice. Drug Metab. Dispos. 2007, 35:1725-1729.
102. Serra G., Forgione A., D'Aquila P.S., Collu M., Fratta W., Gessa G.L. Possible mechanism of antidepressant effect of L-sulpiride. Clin. Neuropharmacol. 1990, 13(Suppl. 1):S76-S83.
103. Shingaki T., Hidalgo I.J., Furubayashi T., Sakane T., Katsumi H., Yamamoto A., Yamashita S. Nasal delivery of P-gp substrates to the brain through the nose-brain pathway. Drug Metab. Pharmacokinet. 2011, 26:248-255.
104. Badcock N.R., Osborne G.A., Nyman T.L., Sansom L.N., Russell W.J., Frewin D.B. Plasma and cerebrospinal fluid concentration of temazepam following oral drug administration. Eur. J. Clin. Pharmacol. 1990, 38:153-155.
105. Product Information: Seldane®, Terfenadine 1996, Marion Merrell Dow, Kansas City, MO.
106. McHenry M.C., Fieker D.H. Newer antibacterial and antimycotic drugs. Critical appraisal. Med. Clin. North Am. 1978, 62:873-897.
107. Reeves D.S., Wilkinson P.J. The pharmacokinetics of trimethoprim and trimethoprim/sulphonamide combinations, including penetration into body tissues. Infection 1979, 7(Suppl. 4):S330-S341.
108. Benya T.J., Wagner J.G. Rapid equilibration of warfarin between rat tissue and plasma. J. Pharmacokinet. Biopharm. 1975, 3:237-255.
109. Garattini S., Bertele V. Efficacy, safety and cost of new drugs acting on the central nervous system. Eur. J. Clin. Pharmacol. 2003, 59:79-84.
110. Crowe S., Cooper D.A., Chambers D.E. Managing HIV. Part 4: Primary therapy. 4.1 Antiretroviral therapies for HIV. Med. J. Aust. 1996, 164:290-295.
111. Ferrari M.D., Roon K.I., Lipton R.B., Goadsby P.J. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001, 358:1668-1675.
112. VolSurf+, version 1.0.4; available from Molecular Discovery Ltd., London, U.K. http://www.moldiscovery.com/soft_vsplus.php.
113. VolSurf+ Manual, available from Molecular Discovery Ltd., London, U.K. http://www.molddiscovery.com/docs/vsplus/.
114. Cruciani G., Meniconi M., Carosati E., Zamora I., Mannhold R. VOLSURF: a tool for drug ADME-properties prediction. Drug Bioavailability: Estimation of Solubility, Permeability, Absorption and Bioavailability 2003, 406-419. WILEY-VCH. H. van de Waterbeemd, H. Lennernäs, P. Artursson (Eds.).
115. Crivori P., Cruciani G., Carrupt P.A., Testa B. Predicting blood-brain barrier permeation from three-dimensional molecular structure. J. Med. Chem. 2000, 43:2204-2216.
116. WOMBAT-PK available from Sunset Molecular Discovery LLC, New Mexico, U.S.A http://www.sunsetmolecular.com.
117. Olah M., Rad R., Ostopovici L., Borá A., Hadaruga N., Hadaruga D., Moldovan R., Fulias A., Mracec M., Oprea T.I. WOMBAT and WOMBAT-PK: bioactivity databases for lead and drug discovery. Chemical Biology: From Small Molecules to Systems Biology and Drug Design 2007, 780-786. WILEY-VCH. S.L. Schreiber, T.M. Kapoor, G. Wess (Eds.).
118. MoKa, version 1.1.0; available from Molecular Discovery Ltd., London, U.K http://www.moldiscovery.com/soft_moka.php.
119. Milletti F., Storchi L., Sforna G., Cruciani G. New and original pKa prediction method using grid molecular interaction fields. J. Chem. Inf. Model. 2007, 47:2172-2181.
120. Leo A.J. Calculating log Poct from structures. Chem. Rev. 1993, 93:1281-1306.
121. Williamson D.F., Parker R.A., Kendrick J.S. The box plot: a simple visual method to interpret data. Ann. Intern. Med. 1989, 110:916-921.
122. Zweig M.H., Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin. Chem. 1993, 39:561-577.
123. Manallack D.T. The pK(a) distribution of drugs: application to drug discovery. Perspect. Med. Chem. 2008, 1:25-38.
124. Orange Canvas, version 2.0b http://www.www.orange.biolab.si.
125. Hartter S., Huwel S., Lohmann T., Abou El Ela A., Langguth P., Hiemke C., Galla H.J. How does the benzamide antipsychotic amisulpride get into the brain? An in vitro approach comparing amisulpride with clozapine. Neuropsychopharmacology 2003, 28:1916-1922.
126. Luer M.S., Hamani C., Dujovny M., Gidal B., Cwik M., Deyo K., Fischer J.H. Saturable transport of gabapentin at the blood-brain barrier. Neurol. Res. 1999, 21:559-562.
127. Thurlow R.J., Hill D.R., Woodruff G.N. Comparison of the uptake of [3H]-gabapentin with the uptake of L-[3H]-leucine into rat brain synaptosomes. Br. J. Pharmacol. 1996, 118:449-456.
128. Nishimura M., Naito S. Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies. Drug Metab. Pharmacokinet. 2005, 20:452-477.
129. Ho R.H., Tirona R.G., Leake B.F., Glaeser H., Lee W., Lemke C.J., Wang Y., Kim R.B. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 2006, 130:1793-1806.
130. Windass A.S., Lowes S., Wang Y., Brown C.D. The contribution of organic anion transporters OAT1 and OAT3 to the renal uptake of rosuvastatin. J. Pharmacol. Exp. Ther. 2007, 322:1221-1227.
131. Kitamura S., Maeda K., Wang Y., Sugiyama Y. Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab. Dispos. 2008, 36:2014-2023.
132. Takeda M., Khamdang S., Narikawa S., Kimura H., Kobayashi Y., Yamamoto T., Cha S.H., Sekine T., Endou H. Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J. Pharmacol. Exp. Ther. 2002, 300:918-924.
133. Zolk O., Solbach T.F., Konig J., Fromm M.F. Structural determinants of inhibitor interaction with the human organic cation transporter OCT2 (SLC22A2). Naunyn Schmiedebergs Arch. Pharmacol. 2009, 379:337-348.
134. Aravagiri M., Yuwiler A., Marder S.R. Distribution after repeated oral administration of different dose levels of risperidone and 9-hydroxy-risperidone in the brain and other tissues of rat. Psychopharmacology 1998, 139:356-363.
135. Elsby R., Surry D.D., Smith V.N., Gray A.J. Validation and application of Caco-2 assays for the in vitro evaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions. Xenobiotica 2008, 38:1140-1164.
136. Clark D.E. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 2. Prediction of blood-brain barrier penetration. J. Pharm. Sci. 1999, 88:815-821.
137. Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 2001, 46:3-26.
138. Timmerman H. Histamine H1 blockers: from relative failures to blockbusters within series of analogues. Analogue-based Drug Discovery 2006, Wiley-VCH. J. Fischer, C.R. Ganellin (Eds.).
139. Chishty M., Reichel A., Siva J., Abbott N.J., Begley D.J. Affinity for the P-glycoprotein efflux pump at the blood-brain barrier may explain the lack of CNS side-effects of modern antihistamines. J. Drug Target. 2001, 9:223-228.
140. Broccatelli F., Carosati E., Cruciani G., Oprea T.I. Transporter-mediated efflux influences CNS side effects: ABCB1, from antitarget to target. Mol. Inform. 2010, 29:16-26.
141. Hendrikse N.H., Schinkel A.H., de Vries E.G., Fluks E., Van der Graaf W.T., Willemsen A.T., Vaalburg W., Franssen E.J. Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography. Br. J. Pharmacol. 1998, 124:1413-1418.
142. Vautier S., Lacomblez L., Chacun H., Picard V., Gimenez F., Farinotti R., Fernandez C. Interactions between the dopamine agonist, bromocriptine and the efflux protein, P-glycoprotein at the blood-brain barrier in the mouse. Eur. J. Pharm. Sci. 2006, 27:167-174.
143. Polli J.W., Olson K.L., Chism J.P., John-Williams L.S., Yeager R.L., Woodard S.M., Otto V., Castellino S., Demby V.E. An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016). Drug Metab. Dispos. 2009, 37:439-442.
144. Chen M.L., Yu L. The use of drug metabolism for prediction of intestinal permeability. Mol. Pharm. 2009, 6:74-81.
145. Larregieu C.A., Benet L.Z. Evaluating the link between passive transcellular permeability and extent of drug absorption and metabolism in humans. Abstract. 25th AAPS Annual Meeting and Exposition, Washington, DC 2011.
146. Bjornsson T.D., Callaghan J.T., Einolf H.J., Fischer V., Gan L., Grimm S., Kao J., King S.P., Miwa G., Ni L., Kumar G., McLeod J., Obach R.S., Roberts S., Roe A., Shah A., Snikeris F., Sullivan J.T., Tweedie D., Vega J.M., Walsh J., Wrighton S.A. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab. Dispos. 2003, 31:815-832.
147. Yao H.M., Chiou W.L. The complexity of intestinal absorption and exsorption of digoxin in rats. Int. J. Pharm. 2006, 322:79-86.
148. Kim M.K., Shim C.K. The transport of organic cations in the small intestine: current knowledge and emerging concepts. Arch. Pharm. Res. 2006, 29:605-616.
149. Alt A., Potthast H., Moessinger J., Sickmuller B., Oeser H. Biopharmaceutical characterization of sotalol-containing oral immediate release drug products. Eur. J. Pharm. Biopharm. 2004, 58:145-150.
150. Liu W., Okochi H., Zhai S.-D., Benet L.Z. Sotalol's permeability in cell, rat, and PAMPA studies. Abstract. 25th AAPS Annual Meeting and Exposition, Washington, DC 2011.
151. Prichard B.N., Tomlinson B. The additional properties of beta adrenoceptor blocking drugs. J. Cardiovasc. Pharmacol. 1986, 8(Suppl. 4):S1-S15.
152. Broccatelli F., Carosati E., Neri A., Frosini M., Goracci L., Oprea T.I., Cruciani G. A novel approach for predicting P-glycoprotein (ABCB1) inhibition using molecular interaction fields. J. Med. Chem. 2011, 54:1740-1751.
153. Alelyunas Y.W., Empfield J.R., McCarthy D., Spreen R.C., Bui K., Pelosi-Kilby L., Shen C. Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate. Bioorg. Med. Chem. Lett. 2010, 20:7312-7316.
154. Ishikawa M., Hashimoto Y. Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry. J. Med. Chem. 2011, 54:1539-1554.
155. Varma M.V., Obach R.S., Rotter C., Miller H.R., Chang G., Steyn S.J., El-Kattan A., Troutman M.D. Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. J. Med. Chem. 2010, 53:1098-1108.
156. Lewis D.F., Lake B.G., Dickins M. Quantitative structure-activity relationships (QSARs) in CYP3A4 inhibitors: the importance of lipophilic character and hydrogen bonding. J. Enzyme Inhib. Med. Chem. 2006, 21:127-132.
157. Vaz R.J., Klabunde T. Antitargets: prediction and prevention of drug side effects. Methods and Principles in Medicinal Chemistry 2008, WILEY-VCH. R. Mannhold, H. Kubinyi, G. Folkers (Eds.).